MoldCo Emerges to Tackle Mold Exposure Health Crisis with Evidence-Based Solutions and $3 Million in Funding

MoldCo, a company based in Cambridge, Massachusetts, has recently emerged from stealth mode to address the significant public health crisis caused by mold exposure. The company, founded by CEO Ariana Thacker, aims to provide evidence-based solutions for individuals suffering from chronic health issues due to mold exposure.

MoldCo has raised $3 million in pre-seed funding, with participation from notable venture capital firms such as Starship Ventures, SALT, Conscience VC, Boost VC, Night Ventures, Bleu Capital, Behind Genius Ventures, and Moth Fund. This funding will be used to expand the company’s services nationwide in 2025.

Thacker, a former venture capital investor and founding partner of Conscience VC, was inspired to start MoldCo after experiencing severe health symptoms due to mold exposure. She delved deep into research and connected with top experts in the field to develop a comprehensive understanding of the health impacts of mold. This knowledge led her to build MoldCo with a vision to provide accessible and affordable treatments and care for individuals facing similar challenges.

MoldCo’s approach is guided by a patented, published, and evidence-based method that has been used to treat over 30,000 patients with Mold Illness, also known as Chronic Inflammatory Response Syndrome (CIRS). The company offers mold-certified clinician care, specialized lab tests, and evidence-based treatments to its customers.

The prevalence of mold in households and office buildings is a significant concern. According to the EPA, 85% of office buildings have experienced water damage, and multiple studies indicate that over 50% of U.S. households have mold, dampness, and water damage. Mainstream medicine has traditionally not recognized or addressed the pervasive and debilitating dangers of mold to people’s health, or its links to various medical conditions. However, there is growing recognition of the many health issues caused by mold, including in large-scale locations such as military housing.

MoldCo is poised to address this long-ignored area by providing a research-backed solution. “Mold can cause debilitating, chronic conditions and has not been adequately addressed by traditional medical institutions. MoldCo is the first company to provide a research-backed solution to address it,” said Sean Hoge, Founder and General Partner at Starship Ventures.

Ritchie Shoemaker, M.D., a recognized world leader and pioneer in the treatment of mold and biotoxin-related illness, and MoldCo’s Founding Physician, emphasized the importance of evidence-based care. “The days of simply living with mold and biotoxin-related illness have been replaced by peer-reviewed treatment protocols, developed from nearly three decades of research and evidence-based care,” he stated.

MoldCo is now accepting patients in select states and invites individuals to join their waitlist on www.moldco.com for early access. The company’s mission is to provide accessible and evidence-based care, treatments, and lab testing for mold toxicity, digitally, enabling individuals to reclaim their health from mold.

The funding from various venture capital firms underscores the significance of MoldCo’s mission and the growing recognition of mold as a critical public health issue. With this support, MoldCo is well-positioned to expand its services and make a meaningful impact on the lives of individuals affected by mold exposure.